Publication date: Dec 27, 2024
Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment? In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy. The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections. With milder pituitary suppression, the fPPOS protocol may be a less costly option for women expected to have a low or suboptimal response if a fresh embryo transfer is not intended. This was a non-inferiority, open-label randomized controlled trial conducted at a tertiary assisted reproduction center. A total of 484 participants were randomized in the study between July 2020 and June 2023 with a 1:1 allocation. Infertile women with a predicted suboptimal ovarian response (
Concepts | Keywords |
---|---|
Freeze | flexible PPOS |
June | freeze-all |
Live | GnRH antagonist |
Medroxyprogesterone | live birth rates |
Ovarian | suboptimal ovarian response |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Gonadorelin |
disease | MESH | live birth |
pathway | REACTOME | Reproduction |
drug | DRUGBANK | Medroxyprogesterone acetate |